§ 90-89. Schedule I controlled substances.
This schedule includes the controlled substances listed or to be listed by whatever official
name, common or usual name, chemical name, or trade name designated. In determining that a substance comes within this schedule, the Commission shall find: a high potential for abuse, no currently accepted medical use in the United States, or a lack of accepted safety for use in treatment under medical supervision. The following controlled substances are included in this schedule:
Any of the following opiates, including the isomers, esters, ethers, salts and salts of isomers, esters, and ethers, unless specifically excepted, or listed in another schedule, whenever the existence of such isomers, esters, ethers, and salts is possible within the specific chemical designation: a.
Acetyl-alpha-methylfentanyl (N[1-(1-methyl-2-phenethyl)-4-piperidinyl]-N-phenylacetamide).
Repealed by Session Laws 1987, c. 412, s. 2.
Alpha-methylthiofentanyl (N-[1-methyl-2-(2-thienyl)ethyl-4-piperidinyl]-N- phenylpropanamide).
1(1-methyl-2-phenyl-ethyl)-4-(N-propanilido) piperidine).
Beta-hydroxfentanyl (N-[1-(2-hydroxy-2-phenethyl)-4-piperidinyl]-N- phenylpropanamide).
Beta-hydroxy-3-methylfentanyl (N-[1-(2-hydroxy-2-phenethyl)-3-methyl-4-piperidinyl]-N- phenylpropanamide).
1-methyl-4-phenyl-4-propionoxypiperidine (MPPP).
3-Methylfentanyl (N-[3-methyl-1-(2-Phenylethyl)-4-Piperidyl]- N-Phenylpropanamide).
3-Methylthiofentanyl (N-[(3-methyl-1-(2-thienyl)ethyl-4-piperidinyl]-N- phenylpropanamide).
Para-fluorofentanyl (N-(4-fluorophenyl)-N-[1-(2-phen-ethyl)-4-piperidinyl]- propanamide.
1-(2-phenethyl)-4-phenyl-4-acetoxypiperidine (PEPAP).
Thiofentanyl (N-phenyl-N-[1-(2-thienyl)ethyl-4-piperidinyl]-propanamide.
Any of the following opium derivatives, including their salts, isomers, and salts of isomers, unless specifically excepted, or listed in another schedule, whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation: a.
Any material, compound, mixture, or preparation which contains any quantity of the following hallucinogenic substances, including their salts, isomers, and salts of isomers, unless specifically excepted, or listed in another schedule, whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation: a.
5-methoxy-3, 4-methylenedioxyamphetamine.
3, 4-Methylenedioxymethamphetamine (MDMA).
N-ethyl-alpha-methyl-3,4-(methylenedioxy)phenethylamine, N-ethyl MDA, MDE, and MDEA).
N-hydroxy-alpha-methyl-3,4-(methylenedioxy)phenethylamine, and N-hydroxy MDA).
Alpha-ethyltryptamine. Some trade or other names: etryptamine, Monase,
Peyote, meaning all parts of the plant presently classified botanically as Lophophora Williamsii Lemaire, whether growing or not; the seeds thereof; any extract from any part of such plant; and every compound, manufacture, salt, derivative, mixture or preparation of such plant, its seed or extracts.
2, 5-dimethoxy-4-ethylamphetamine. Some trade or other names: DOET.
Ethylamine analog of phencyclidine. Some trade or other names: N-ethyl-1-phenylcyclohexylamine, (1-phenylcyclohexyl) ethylamine, N-(1-phenylcyclohexyl) ethylamine, cyclohexamine, PCE.
Pyrrolidine analog of phencyclidine. Some trade or other names: 1-(1-phenylcyclohexyl)-pyrrolidine, PCPy, PHP.
Thiophene analog of phencyclidine. Some trade or other names: 1-[1-(2-thienyl)-cyclohexyl]-piperidine,
1-[1-(2-thienyl)cyclohexyl]pyrrolidine; Some other names: TCPy.
Any material compound, mixture, or preparation which contains any quantity of the following substances having a depressant effect on the central nervous system, including its salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation, unless specifically excepted or unless listed in another schedule: a.
acid; sodium oxybate; sodium oxybutyrate.
Stimulants. – Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation that contains any quantity of the following substances having a stimulant effect on the central nervous system, including its salts, isomers, and salts of isomers: a.
Methcathinone. Some trade or other names: 2-(methylamino)- propiophenone,
N-methylcathinone, methylcathinone, AL-464, AL-422, AL-463, and UR1432.
(+-)cis-4-methylaminorex [(+-)cis-4,5-dihydro-4-methyl-5-phenyl-2-oxazolamine] (also known as 2-amino-4-methyl-5-phenyl-2-oxazoline).
N,N-dimethylamphetamine. Some other names: N,N,alpha-tri- methylbenzeneethaneamine; N,N,alpha-trimethylphenethylamine.
4-methylmethcathinone (also known as mephedrone).
3,4-Methylenedioxypyrovalerone (also known as MDPV).
A compound, other than bupropion, that is structurally derived from 2-amino-1-phenyl-1-propanone by modification in any of the following ways: (i) by substitution in the phenyl ring to any extent with alkyl, alkoxy, alkylenedioxy, haloalkyl, or halide substituents, whether or not further substituted in the phenyl ring by one or more other univalent substituents; (ii) by substitution at the 3-position with an alkyl substituent; or (iii) by substitution at the nitrogen atom with alkyl or diakyl groups or by inclusion of the nitrogen atom in a cyclic structure.
2,5-Dimethoxy-4-(n)-propylthiophenethylamine. (1971, c. 919, s. 1; 1973, c. 476, s. 128; c. 844; c. 1358, ss. 4, 5, 15; 1975, c. 443, s. 1; c. 790; 1977, c. 667, s. 3; c. 891, s. 1; 1979, c. 434, s. 1; 1981, c. 51, s. 9; 1983, c. 695, s. 1; 1985, c. 172, ss. 1-3; 1987, c. 412, ss. 1-5; 1989 (Reg. Sess., 1990), c. 1040, s. 1; 1993, c. 319, ss. 1, 2; 1995, c. 186, ss. 1-3; c. 509, s. 135.1(c); 1997-456, ss. 12, 27; 1999-165, s. 1; 2000-140, s. 92.2(a); 2011-12, s. 1; 2011-326, s. 14(a), (b).)
The Nortriptyline Therapeutic Window: A systematic review Abstract dress variation in study designs and other study-level variables. Background: Some studies have found a curvilin-ear relationship between the nortriptyline plasmaIn thirty-three clinical trials or obser-concentration and the clinical rating of depressionvational studies, some evidence was found for ain those treated. The co
.L. , DESMECHT D., LEKEUX P. : Physiologie et physiopathologie du facteur d'acti-vation plaquettaire et perspectives thérapeutiques de ses antagonistes. Ann. Méd. Vét., 1995, 139, 99-2. LEKEUX P., VAN DE WEERDT M.-L. : Use of anti nflammatory drugs in the treatment of bovine respirat-ory disease complex. Proceedings of a Symposium held in conjunction with XIX World Buiatrics Con-gress, Edi